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Abstract
Background: The dysregulation of gene expression in the TNF-TNFR superfamily has been involved in various
human cancers including non-small cell lung cancer (NSCLC). Furthermore, functional polymorphisms in TNF-a and
TNFRSF1B genes that alter gene expression are likely to be associated with risk and clinical outcomes of cancers.
However, few reported studies have investigated the association between potentially functional SNPs in both TNF-
a and TNFRSF1B and prognosis of NSCLC patients treated with chemoradiotherapy.
Methods: We genotyped five potentially functional polymorphisms of TNF-a and TNFRSF1B genes [TNF-a -308 G>A
(rs1800629) and -1031 T>C (rs1799964); TNFRSF1B +676 T>G (rs1061622), -1709A>T(rs652625) and +1663A>G
(rs1061624)] in 225 NSCLC patients treated with chemoradiotherapy or radiotherapy alone. Kaplan-Meier survival
analysis, log-rank tests and Cox proportional hazard models were used to evaluate associations between these
variants and NSCLC overall survival (OS).
Results: We found that the TNFRSF1B +676 GG genotype was associated with a significantly better OS of NSCLC
(GG vs. TT: adjusted HR = 0.38, 95% CI = 0.15-0.94; GG vs. GT/TT: adjusted HR = 0.35, 95% CI = 0.14-0.88). Further
stepwise multivariate Cox regression analysis showed that the TNFRSF1B +676 GG was an independent prognosis
predictor in this NSCLC cohort (GG vs. GT/TT: HR = 0.35, 95% CI = 0.14-0.85), in the presence of node status (N2-3
vs. N0-1: HR = 1.60, 95% CI = 1.09-2.35) and tumor stage (T3-4 vs. T0-2: HR = 1.48, 95% CI = 1.08-2.03).
Conclusions: Although the exact biological function for this SNP remains to be explored, our findings suggest a
possible role of TNFRSF1B +676 T>G (rs1061622) in the prognosis of NSCLC. Further large and functional studies are
needed to confirm our findings.
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Background
Lung cancer is the most common tobacco-induced can-
cer and the leading cause of cancer-related deaths
worldwide, with an estimated 1.61 million new cases
and 1.38 million deaths in 2008 [1]. About 80% of pri-
mary lung cancer patients are non-small cell lung cancer
(NSCLC), and one third of the patients were diagnosed
at a locally advanced stage [2]. Despite significant
advances in early detection and combination treatment
including radiotherapy and chemotherapy in the last few
decades, the prognosis of lung cancer remains poor,
with a five-year overall survival rate of about 15% in the
United States [3]. The tumor, lymph node, metastasis
(TNM) staging system of lung cancer has been used as
a guide for predicting prognosis [4]; however, dramati-
cally different survival outcomes in NSCLC patients
with the same pathological or clinical stage and the
same treatments suggest that other factors may play an
important role in the prognosis of NSCLC. Therefore,
the discovery and application of novel prognostic bio-
markers could help predict clinical outcomes and
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NSCLC patients.
Tumor necrosis factor alpha (TNF-a) is a pro-inflam-
matory cytokine produced by activated macrophages
and exerts its action through binding to its two cognate
cell surface receptors, TNFRSF1A/TNFR1 (p55/60) and
TNFRSF1B/TNFR2 (p75/80). It is well known that TNF
and its superfamily members have both beneficial and
harmful activities, playing a role as a “double-edged
sword” [5]. Although TNF was discovered as a cytokine
that could kill tumor cells, it is now clear that TNF can
also contribute to tumorigenesis by mediating the prolif-
eration, invasion and metastasis of tumor cells [5]. The
dysregulation of gene expression in the TNF-TNFR
superfamily has been reported to be involved in the
development and prognosis of various human cancers
including NSCLC [6-12]. For example, studies indicated
that high serum concentrations of TNF were associated
with a significantly longer survival in NSCLC patients
after chemotherapy [12] and that TNFRSF1B had a sig-
nificantly different expression profile in 5-FU-non-
responding and responding liver cancer patients [11].
Additionally, recent reports found that TNF-a was
involved in the pathogenesis of radiation-induced lung
injury [13] and that inhibiting the TNF-a pathway was a
novel radioprotection strategy [14]. These observations
suggest that TNF and TNFRSF1B m a yp l a yar o l ei n
patients’ treatment response, toxicity, and survival.
Thus, genetic variations in TNF and TNFRSF1B that
alter gene expression and/or protein production may be
potential candidates for prognosis predictors of NSCLC
patients.
TNF-a and TNFRSF1B genes are highly polymorphic,
and several functional single nucleotide polymorphisms
(SNPs) in these two genes have been identified, which
may contribute to differences in expression levels of the
genes or protein products [15-20]. Of a particular signif-
icance are two TNF-a SNPs (SNP -308 G>A and -1031
T>C in the promoter region) and one TNFRSF1B SNP
(+676 T>G in exon 6), which have been widely investi-
gated for their associations with susceptibility to and
progression and prognosis of various cancers [21-37].
However, to the best of our knowledge, no published
study has investigated associations between potentially
functional SNPs of these two genes and prognosis of
NSCLC patients treated with chemoradiotherapy. There-
fore, we performed a case-only study with 225 NSCLC
patients treated with chemoradiotherapy or radiotherapy
alone to investigate whether these three SNPs (SNP
-308 G>A and -1031 T>C in TNF-a,a n d+ 6 7 6T > G )a s
well as the other two potentially functional SNPs
(-1709A>T and +1663A>G in TNFRSF1B) are associated
with overall survival of NSCLC.
Methods
Study population
Epidemiological and clinical data were available from a
larger dataset of 576 NSCLC patients who were treated
with definitive radiation at The University of Texas M.
D. Anderson Cancer Center (Houston, TX) between
1998 and 2006. The detailed information about these
subjects has been described elsewhere [38]. After the
exclusion of those patients who had surgical resection
or had been treated elsewhere before coming to M. D.
Anderson, a total of 225 NSCLC patients treated with
chemoradiotherapy or radiotherapy alone were included
in this analysis; The study was approved by the M. D.
Anderson Cancer Center institutional review board in
compliance with Health Insurance Portability and
Accountability Act (HIPAA) regulations.
SNP selection
We screened the NCBI dbSNP database (http://www.
ncbi.nlm.nih.gov/, build 131) and Hapmap database
(http://www.hapmap.org/, Rel 27) for common, poten-
tially functional SNPs with a minor allele frequency
(MAF) ≥ 0.05 in CEU populations, i.e., those SNPs
located in the 5’ near gene, 5’-a n d3 ’-untranslated
regions and coding region of TNF-a and TNFRSF1B.
Meanwhile, linkage disequilibrium (LD) analysis and
bioinformatics prediction by SNPinfo (http://snpinfo.
niehs.nih.gov/) [39] were also performed to optimize
SNP selection. Finally, a total of five SNPs (TNF-a -308
G>A, TNF-a -1031 T>C, and TNFRSF1B +676 T>G,
TNFRSF1B -1709A>T and TNFRSF1B+1663A>G) were
selected for genotyping. Among these, three SNPs are
located in the promoter regions of the genes (TNF-a
-308 G>A, TNF-a -1031 T>C, and TNFRSF1B
-1709A>T), which are predicted to affect the binding of
some transcription factors. One SNP (TNFRSF1B +676
T>G) causes a missense change and the other
(TNFRSF1B +1663A>G) is located in the 3’-untranslated
region, which may affect miRNA binding.
Genotyping
Genomic DNA was isolated from the buffy coat fraction
of each blood sample with a Blood Mini Kit (Qiagen,
Valencia, CA) according to the manufacturer’si n s t r u c -
tions. Genotypes of the three selected SNPs (SNP -308
G>A and -1031 C>T in TNF-a, and -1709A>T in
TNFRSF1B ) were determined by the primer-introduced
restriction analysis (PIRA)-PCR assay. The primers used
for TNF-a -308 G >A, TNF-a -1031 T>C and TNFRSF1B
-1709A>T were 5’-GCAATAGGTTTTGAGGGCCATG-
3’ (sense) and 5’-TTTGGAAAGTTGGGGACACACA-
3’(anti-sense); 5’-GGGAAGCAAAGGAGAAGCTGA-
GAACA-3’ (sense) and 5’-GGGGGGTCCCCATACTC
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GACCAATGAG-3’ (sense) and 5’-CTTGAATTCGT
TCCCAGGATGG-3’ (anti-sense), respectively. The mis-
matched G, C and A were respectively introduced into
the sense primers at 6 bp, 2 bp and 2 bp from these three
polymorphic sites to create NcoI, NlaIII and MlyI restric-
tion sites. Additionally, TNFRSF1B +676T>G and
+1663A>G were genotyped by the polymerase chain
reaction-restriction fragment length polymorphism
(PCR-RFLP) method with the primers 5’-CTCCT
CCTCCAGCTGTAACG-3’ (sense) and 5’-CCAACTG-
GAAGAGCGAAGTC-3’ (anti-sense), and 5’-AGGCC
CCCACCACTAGGACTCT-3’ (sense) and 5’-GTTGT
GGAAAGCCTCTGCTGC-3’ (anti-sense), respectively.
The following PCR conditions were performed: 5 min of
initial denaturation at 95°C followed by 35 cycles of 30 s
at 95°C; 45 s at 64°C (TNF-a -308 G >A) or 59°C (TNF-a
-1031 C>T) or 64°C (TNFRSF1B +676 T>G) or 59°C
(TNFRSF1B -1709A>T) or 62°C (TNFRSF1B +1663A>G),
respectively; 45 s at 72°C; and a final 10-min step at 72°C
for final extension.
All the PCR products were digested with the restriction
enzymes overnight (NcoI for TNF-a -308 G >A, NlaIII for
TNF-a -1031 C>T and TNFRSF1B +676 T>G, and MlyI
for TNFRSF1B -1709A>T) and MspA1I for TNFRSF1B
(+1663A>G), and the products were separated in 3% Meta-
Phor agarose gel. After completion of gel electrophoresis,
the TNF-a -308 GG genotype produced two bands (127-
and 18-bp), AA produced a single band (145-bp), and AG
displayed all three bands (145-, 127-, and 18-bp) (Figure
1A); the TNF-a -1031 CC genotype resulted in two bands
of 108- and 86-bp, TT produced three bands of 108-, 62-
and 24-bp, and CT produced four bands (108-, 86-, 62-
and 24-bp) (Figure 1B); the TNFRSF1B +676 TT genotype
produced two bands (200- and 48-bp), GG produced a sin-
gle band (248-bp), and TG displayed all three bands (248-,
200- and 48-bp) (Figure 1C); TNFRSF1B -1709 TT geno-
type produced two bands of 136- and 24-bp, AA resulted
in a single 160-bp band, and TA displayed all three bands
(160-, 136- and 24-bp) (Figure 1D); and TNFRSF1B
+1663AA resulted in a single 128-bp band, GG genotype
produced another single band of 104-bp, and GA displayed
all two bands (128-, and 104-bp) (Figure 1E)
Genotyping was performed without knowing the sub-
jects’ disease status. Two research assistants indepen-
dently read the gel pictures and performed the repeated
assays, if they did not reach a consensus on the tested
genotype. About 10% of the samples were randomly
selected to perform the repeated assays, and the results
were 100% concordant.
Statistical analysis
The two-sided c
2 tests were performed to determine any
statistically significant differences in the distributions of
the TNF-a and TNFRSF1B genotypes by demographic
variables and clinical features. Median survival time
(MST) was calculated, and mean survival time was pre-
sented when the MST could not be calculated. Kaplan-
Meier estimates were used to estimate overall survival
(OS) among four genotype groups, and the log-rank test
was used to test for equality of the survival distributions.
Univariate analysis and multivariate Cox proportional
hazards models were conducted to estimate the effect of
each genotype on survival with or without the presence
of known prognostic factors. Cox stepwise hazards
regression model was also conducted to determine inde-
pendently predictors of NSCLC prognosis, with a signifi-
cance level of 0.050 for entering and 0.051 for removing
the respective explanatory variables. Haplotype frequen-
cies and individual haplotypes based on the observed
genotypes were generated by using SAS PROC HAPLO-
TYPE. Analyses were performed by using SAS statistical
package version 9.1 (SAS Institute Inc., Cary, NC).
Results
Patient characteristics and clinical features
As shown in Table 1, 225 patients were included in the
final analyses, of which 155 deaths were observed during
the follow-up period, and the overall MST was 23
months. Among the cases, 79 (35.1%) were adenocarci-
noma, 71 (31.6) squamous cell carcinoma, and 75
(33.3%) other type of NSCLC. According to the AJCC
6
th edition stage grouping criteria [40], 33 cases (14.7%)
were stage I-II, and 192 (85.3%) were stage III-IV. In
this study, all cases received radiotherapy with a median
radiation dose of 63.0 (range 50.4-84.0) Gy at 1.8 to 2
Gy per fraction once a day. Platinum and taxane-based
chemotherapy was also given to 163 (72.4%) patients.
None of the patients received surgery. Log-rank test
showed that, in this study population, there were no sig-
nificant differences in NSCLC-specific survival by age
(log-rank P = 0.117), ethnicity (P = 0.827), smoking sta-
tus (P = 0.457), histology (P = 0.092), Karnofsky’sp e r -
formance scores (KPS, P = 0.405), chemotherapy status
(P = 0.407) and radiotherapy dose (P = 0.706). However,
sex, tumor stage, and node status were significantly
associated with MST of NSCLC (log-rank P = 0.036,
0.010 and 0.023, respectively). Because these variables
may be confounding factors for the effect of the geno-
types on OS, they were further adjusted in the multi-
variable analysis.
TNF-a and TNFRSF1B genotypes and NSCLC survival
T h eg e n o t y p ed i s t r i b u t i o n so ft h ef i v eS N P si nTNF-a
and TNFRSF1B and their associations with OS are sum-
marized in Table 2. In all patients, only genotypes of
TNFRSF1B +676 G>T (rs1061622) were statistically sig-
nificantly associated with OS (log-rank P =0 . 0 4 0i na n
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sive model, Figure 2B). After adjustment for age, sex,
ethnicity, smoking status, tumor histology, Karnofsky’s
performance scores, tumor stage, application of che-
motherapy and radiotherapy dose, the TNFRSF1B +676
GG variant homozygous genotype remained to be asso-
ciated with a significantly decreased risk of death from
NSCLC (adjusted HR = 0.38, 95% CI = 0.15-0.94 for
GG vs. TT; adjusted HR = 0.35, 95% CI = 0.14-0.88 for
GG vs. GT/TT), but this association was not observed
for the other four SNPs investigated in this study.
In order to confirm an independent role of SNPs in
NSCLC survival, we further performed a multivariate
stepwise analysis with selected demographic character-
istics and clinical features in different genetic models
of TNFRSF1B +676 T>G (rs1061622) on NSCLC survi-
val. Three variables (tumor stage, node status and
rs1061622 GG vs. GT/TT) were identified in the
regression model with a significance level of 0.050 for
entering and 0.051 for removing a variable (Table 3),
suggesting the independent effect of these three factors
on death risk of NSCLC. When age and sex were
forced into the final model, the rs1061622 GG geno-
type remained a significantly favorable predictor for
NSCLC survival (GG vs. GT/TT: HR = 0.39, 95% CI =
0.16-0.95) (Table 3).
Figure 1 PCR-based genotyping for TNF-a -308 G>A (A), TNF-a -1031C>T (B), TNFRSF1B +676 G>T (C), and TNFRSF1B -1709 A>T (D).
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As shown in Figure 3A-E, we further evaluated cumula-
tive survival in subgroups by TNFRSF1B +676 T>G
(rs1061622) genotypes and selected factors including
age, ethnicity, tumor stage and node status. The longest
survival was observed in subgroups with both rs1061622
GG and age≤62 years (MST = 44.0 months), or white
ethnicity (MST = 48.3 months), or T0-2 tumors (MST =
48.3 months), or N2-3 tumors (MST = 44.0 months),
compared with the poorest survival in subgroups with
both rs1061622 GT/TT and age>62 years (MST = 20.7
months), or non-white (MST = 21.0 months), or T3-4
tumors (MST = 18.2 months), or N0-1 tumors (MST =
29.2 months); however, small sample size in these
subgroups might have led to a suboptimal statistical
power to detect a statistical difference in the survival
time. We also conducted the stratification analysis by
histology and different treatments, but the numbers of
patients in subgroups were too small, and no significant
results were found in every stratum (data not shown).
In addition, we also evaluated the combined effect of
these polymorphisms on NSCLC survival by using the
haplotype analysis. The results showed that TNF-a
-308G/-1031T (GT) and TNFRSF1B +676T/+1663A/-
1709A (TAA) were the most common haplotypes in the
patients with the frequencies of 63.3% and 40.2%,
respectively. However, we did not found significant asso-
ciations between other haplotypes and OS of NSCLC
Table 1 Characteristics of patients (N = 225) and overall survival (OS)
Variables Patients No. (%) Deaths No. (%) MST (Months) Log-rank P
a
Age
≤62 years 111 (49.3) 72 (46.5) 25.6 0.117
>62 years 114 (50.7) 83 (53.5) 21.1
Gender
Female 102 (45.3) 65 (41.9) 26.7 0.036
Male 123 (54.5) 90 (58.1) 22.3
Ethnicity
White 162 (72.0) 117 (75.5) 23.5 0.827
Non-White 63 (28.0) 38 (24.5) 22.3
Smoke
b
Ever 205 (91.5) 143 (92.9) 23.4 0.457
Never 19 (8.5) 11 (7.1) 21.1
Histology
Adenocarcinoma 79 (35.1) 48 (31.0) 27.3 0.092
Squamous cell 71 (31.6) 51 (32.9) 23.2
Others
b 75 (33.3) 56 (36.1) 19.0
KPS
c
90-100 51 (25.4) 34 (22.7) 25.1 0.405
80 118 (58.7) 90 (60.0) 22.1
<80 32 (15.9) 26 (17.3) 21.1
Tumor stage
c
T0-2 127 (57.2) 81 (52.3) 26.9 0.010
T3-4 95 (42.8) 74 (47.7) 19.2
Node status
c
N0-1 59 (26.7) 35 (22.6) 29.0 0.023
N2-3 162 (73.3) 120 (77.4) 20.7
Chemotherapy
Yes 163 (72.4) 113 (72.9) 26.9 0.407
No 62 (27.6) 42 (27.1) 22.1
Radiotherapy dose
d
≤63.0 Gy 115 (51.1) 77 (49.7) 22.7 0.706
>63.0 Gy 110 (48.9) 78 (50.3) 25.1
MST: median survival time; KPS: Karnofsky’s performance scores
a Log-rank test.
b Others include large cell, undifferentiated and mixed-cell carcinomas.
c Some missing data.
dThe median radiotherapy dose is 63 Gy.
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(data not shown), which is likely due to limited study
power.
Discussion
In the present study, we examined the effect of five
selected polymorphisms in TNF-a and TNFRSF1B on
survival of NSCLC patients treated with chemora-
diotherapy or radiotherapy alone. We found that the
TNFRSF1B +676 GG (rs1061622) variant homozygous
genotype was associated with a significantly improved
survival of NSCLC in this non-Hispanic patient
population. Such an effect was not observed for other
SPNs under investigation.
Tumor necrosis factor-alpha (TNF-a) executes multi-
ple functions in immunity, inflammation, differentiation,
control of cell proliferation, and apoptosis through dis-
tinct receptors known as TNF receptor type I (TNFR1)
and type II (TNFR2) [5]. Expression levels of TNF-a
and its receptors have been linked to development and
treatment outcomes of solidt u m o r si n c l u d i n gN S C L C
[6,7,10]. The expression of TNF-a is mostly regulated at
the transcriptional level, and polymorphisms within the
TNF-a promoter have been related to TNF-a levels
Table 2 Associations between TNF-a and TNFRSF1B genotypes and overall survival of NSCLC patients
Genotypes No. of patients No. of Deaths MST (months) Crude HR (95% CI) Adjusted HR (95% CI)
a Adjusted P
a
TNF-a -308 G>A (rs1800629)
GG 163 112 (68.7) 23.5 1.00 1.00
AG 56 39 (69.6) 23.2 1.04 (0.72-1.50) 0.95 (0.65-1.40) 0.802
AA 6 4 (66.7) 18.1 1.18 (0.44-3.21) 1.10 (0.39-3.11) 0.859
AG+AA 61 43 (70.5) 23.1 1.05 (0.74-1.50) 0.96 (0.67-1.40) 0.849
AG+GG 219 151 (68.9) 23.4 1.00 1.00
AA 6 4 (66.7) 18.1 1.17(0.43-3.16) 1.11 (0.40-3.13) 0.840
TNF-a -1031T>C (rs1799964)
TT 137 95 (69.3) 23.4 1.00 1.00
CT 77 50 (64.9) 22.1 0.96 (0.68-1.35) 0.89 (0.62-1.28) 0.542
CC 11 10 (90.9) 23.1 1.28 (0.67-2.46) 1.41 (0.70-2.87) 0.341
CT+CC 88 60 (68.2) 23.1 1.00 (0.72-1.38) 0.95 (0.68-1.34) 0.785
CT+TT 214 145 (67.8) 23.4 1.00 1.00
CC 11 10 (90.9) 23.1 1.30(0.68-2.47) 1.46 (0.73-2.94) 0.289
TNFRSF1B +676 T>G (rs1061622)
TT 124 85 (68.5) 23.4 1.00 1.00
GT 90 65 (72.2) 21.8 1.10 (0.80-1.52) 1.19 (0.84-1.69) 0.323
GG 11 5 (45.5) 41.1
b 0.36 (0.14-0.88) 0.38 (0.15-0.94) 0.037
GT+GG 101 70 (69.3) 23.2 0.96 (0.70-1.31) 1.01 (0.72-1.42) 0.937
GT+TT 214 150 (70.1) 22.7 1.00 1.00
GG 11 5 (45.5) 41.1
b 0.34 (0.14-0.84) 0.35 (0.14-0.88) 0.026
TNFRSF1B -1709A>T (rs652625)
AA 207 144 (69.6) 23.2 1.00 1.00
AT 15 9 (60.0) 27.8 0.86 (0.44-1.69) 0.85 (0.42-1.71) 0.649
TT 3 2 (66.7) 15.1 0.94 (0.23-3.82) 1.02 (0.23-4.47) 0.976
AT+TT 18 11 (61.1) 26.7 0.88 (0.47-1.62) 0.87 (0.46-1.67) 0.685
AT+AA 222 153 (68.9) 23.4 1.00 1.00
TT 3 2 (66.7) 15.1 0.95 (0.24-3.85) 1.05 (0.24-4.58) 0.946
TNFRSF1B +1663A>G(rs1061624)
AA 67 46 (68.7) 23.4 1.00 1.00
AG 89 63 (70.8) 21.1 1.06 (0.73-1.53) 0.98 (0.68-1.43) 0.921
GG 62 41 (66.1) 28.1 0.84 (0.56-1.26) 0.79 (0.52-1.20) 0.269
AG+GG 151 104 (68.9) 24.0 1.03(0.73-1.46) 0.96 (0.67-1.37) 0.824
AG+AA 156 109 (69.9) 22.7 1.00 1.00
GG 62 41 (66.1) 28.1 0.84 (0.59-1.20) 0.81 (0.56-1.18) 0.275
MST: median survival time; HR: hazard ratio
aAdjusted for age, gender, ethnicity, smoking status, tumor histology, KPS, tumor stage, node status, application of chemotherapy and radiotherapy dose.
bMean survival time was provided when MST could not be calculated.
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of TNF-a has been reported to be associated with
higher expression levels of TNF-a [41] and thus sus-
ceptibility to numerous cancers, including cancers of the
stomach [25], breasts [34], oral cavity [31,32], bladder
[35] and lung [25]. Additionally, several studies also
found that TNF-a-308 G/A and another SNP in the
promoter of TNF-a (-1031C>T, rs1799964) were signifi-
cantly associated with prognosis of bladder cancer and
breast cancer [28,29,36], clinical characteristics of color-
ectal cancer, and severity of lung cancer [25]. However,
no significant associations between these two SNPs and
NSCLC survival were found in our study, which was
consistent with recent data that suggested the lack of
associations between TNF-a-308 G/A or TNF-a-1031
T>C and the prognosis of several other cancers, includ-
ing gastric cancer [42], colorectal cancer [43], Hodgkin’s
lymphoma [44], and breast cancer [45]. Such a discre-
pancy of reported studies might be explained by differ-
ent tumor sites and tumor progression features, ethnic
difference with diverse genetic background, different
therapeutic strategies, and either false negative or false
positive results because of the small sample sizes in pre-
viously published studies.
Interestingly, logistic and stepwise regression analysis
in our study indicated that TNFRSF1B rs1061622 GG
might be an independent predictor for survival of
NSCLC patients treated with chemoradiotherapy or
Figure 2 Overall survival curves by genotypes of TNFRSF1B +676 T>G (rs1061622) in additive model (A) and recessive model (B). The P
values were obtained from the unadjusted log-rank test.
a Mean survival time was provided when MST could not be calculated.
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receptor found on circulating T lymphocytes, which
functions both as a TNF antagonist by neutralizing it
and as an agonist by facilitating interaction between
TNF and TNFR1 at the cell surface [46]. rs1061622 is
located in the exon 6 of TNFRSF1B (M196R) that causes
a functional amino acid change from methionine (M) to
arginine (R) [20], which is postulated to affect the pro-
teolytic cleavage of the membrane bound TNFRSF1B to
a soluble form as well as TNF binding and/or TNF
induced apoptosis by impaired NF-B signaling [47,48].
However, the results from published studies on asso-
ciations between rs1061622 and prognosis of cancers
were controversial rather than conclusive. For example,
a Tunisian study showed significant associations of
TNFRSF1B +676 T>G (rs1061622) with susceptibility
and survival of breast cancer patients [26], but another
Japanese study suggested no association between this
S N Pa n dp r o g n o s i so fe s o p h a g e a ls q u a m o u sc e l lc a r c i -
noma [49]. Up to now, no published study investigated
the association between TNFRSF1B +676 T>G
(rs1061622) and lung cancer survival, and the exact bio-
logical mechanism underlying this association in our
study remains to be investigated. It is possible that this
SNP affects the function of TNFRSF1B and enhances
radiotherapy or chemotherapy efficacy through inhibit-
ing tumor therapy resistance. Another possibility is that
this SNP may change the expression level of TNFRSF1B
and influence the character of immunological response
to infection in lung cancer patients, finally resulting in
Table 3 Results of stepwise Cox regression analysis on NSCLC
Variables b SE HR 95% CI P
Stepwise Regression Analysis
Node status (N2-3 vs. N0-1) 0.472 0.195 1.60 1.09-2.35 0.015
Tumor stage (T3-4 vs. T0-2) 0.392 0.162 1.48 1.08-2.03 0.016
TNFRSF1B +676 T>G (GG vs GT/TT) -1.061 0.457 0.35 0.14-0.85 0.020
Final Regression Model
Age (>62 years vs. ≤62 years) 0.288 0.165 1.33 0.97-1.84 0.081
Sex (Male v.s Female) 0.252 0.165 1.29 0.93-1.78 0.126
Node status (N2-3 vs. N0-1) 0.511 0.196 1.67 1.14-2.45 0.009
Tumor stage (T3-4 vs. T0-2) 0.392 0.163 1.48 1.08-2.04 0.016
TNFRSF1B +676 T>G (GG vs GT/TT) -0.954 0.459 0.39 0.16-0.95 0.038
SE: standard error; HR: hazard ratio
Figure 3 Overall survival curves by genotypes of TNFRSF1B +676 T>G (rs1061622) and selected factors including age (A), ethnicity (B),
tumor stage (C) and node status(D). The P values were obtained from the unadjusted log-rank test.
a Mean survival time was provided when
MST could not be calculated.
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Page 8 of 10t h ed i f f e r e n c eo fs u r v i v a li n NSCLC [50]. Furthermore,
we also found that cumulative survival was different in
subgroups by TNFRSF1B +676 T>G (rs1061622) geno-
types and selected factors including age, ethnicity,
tumor stage and node status. Although our sample size
was relatively small in these subgroups, it provided a
clue that effect of this SNP on prognosis of NSCLC may
be dependent on patients’ characteristics and clinical
features as well. However, the exact functional relevance
of this SNP in the prognosis of NSCLC patients treated
with chemoradiotherapy remains to be explored.
Although our study reported some new findings about
polymorphisms of TNF and TNFRSF1B genes in NSCLC
patients, several potential limitations should be taken
into consideration. Firstly, our sample size is relatively
small with a limited statistical power to evaluate interac-
tions between the studied polymorphisms and clinical
factors including tumor stage and node status. For the
same reason, the results from our subgroups by
TNFRSF1B +676 T>G (rs1061622) genotypes and
selected factors need validation by larger studies. Sec-
ondly, only five potentially functional SNPs in TNF and
TNFRSF1B were included in our study, which is far
from comprehensive. Indeed, both genes are highly
polymorphic, and it is possible that some important
SNPs may have been missed or the observed association
may have been due to other polymorphisms in LD with
the studied ones. Again, much larger studies would have
the statistical power to confirm the associations of more
SNPs with OS in such a patient population.
Conclusion
In summary, in this cohort of NSCLC patients, we iden-
t i f i e dap o s s i b l er o l eo fTNFRSF1B +676 T>G in the
prognosis of NSCLC. However, replication studies with
diverse ethnic groups, larger sample sizes and functional
characterizations are warranted. Currently, we have
ongoing projects that help continue recruiting similar
patients for additional analysis in the future.
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